Cell Analysis Market: Growth, Size, Share, and Trends

Market Growth Outlook Summary

The global cell analysis market growth forecasted to transform from $20.2 billion in 2023 to $33.9 billion by 2028, driven by a CAGR of 10.9%. Increase in the preference for cell-bsaed assays along with strong funding for cell-based research is expected to drive the market growth. The conventional methods of toxicity and drug safety assessment (involving animal testing) are expensive, time-consuming, and offer low-throughput. In this regard, modern cell-based assays merge the advantages of cell cultures and animal models to allow researchers to identify problems with lead compounds in early screening, ensuring greater efficiency in the drug discovery and development process.

Attractive Opportunities in the Cell Analysis Market

To know about the assumptions considered for the study, Request for Free Sample Report

Cell Analysis Market Dynamics

DRIVER: Growing number of drug discovery activities

Adoption of cell-based screening assays has increased in he drug discovery activities to understand associated complexities. Additionally, advances in cell biology, bioinformatics, molecular biology, genomics, and proteomics have generated large volumes of data, owing to which the use of cell-based assays in the drug development process has gained importance. Similarly, the Human Genome Project has generated a number of targets on which drug screening experiments can be carried out. This rapid expansion in drug targets and drug leads in recent years has accelerated the development of cell-based assays for primary and secondary screening in drug discovery.

RESTRAINT: High cost of instruments and restrictions on reagent use

The introduction of high-throughput screening (HTS) and high-content screening (HCS) technologies in cell analysis has increased their reliability. However, these technologies have also resulted in a significant increase in the cost of instruments. Moreover, the time and cost involved in each HTS process are directly proportional to the target molecule’s complexity; consequently, the higher the complexity, the greater the cost. In biopharmaceutical companies, the overall cost of production of biopharmaceuticals has increased considerably due to the use of these expensive systems.

OPPORTUNITY: Application of novel cell-based assays in cancer research

In the last few decades, the incidence and prevalence of cancer have increased significantly across the globe, and this trend is expected to continue in the coming years. In an effort to reduce cancer incidence and mortality, the demand for novel approaches that offer effective cancer diagnosis and treatment has increased in recent years. In this regard, some recent studies have been published that highlight the importance of cell-based assays in cancer research.

Global Cell Analysis Ecosystem Analysis

The cell analysis industry ecosystem comprises raw material suppliers, service providers, and end users such as pharmaceutical & biotechnology companies, CROs, hospitals, and diagnostic laboratories. Raw material suppliers & product manufacturers offer various supplies & products for different cell analysis processes. Cell analysis companies entered into partnerships with their clients, such as pharmaceutical companies, in order to design a strategy for the design and development of cell analysis products, including assays, reagents, instruments & accessories, and software solutions. This long-term relationship enables partners to develop cell-based research experiments successfully and bring new therapeutic and diagnostic solutions to the market. Also, as partners work together for a long time, the volume of work contracted out can expand, depending on how comfortable both the partners are in taking the partnership forward.

The software segment of the cell analysis industry is expected to grow at the highest rate during the forecast period

Based on product & service, the global cell analysis market is segmented into reagents & consumables, instruments, accessories, software, and services. The reagents & consumables segment accounted for the largest share of the market in 2022. Prominent companies are providing flow cytometry reagents as directly conjugated products. Companies are introducing high-quality reagents with an enhanced geographic reach contributing to the largest share of the reagents & consumables market. Innovative offerings addressing complex datasets with multiple analytical modalities for effective interpretation is the key contributing factor to the segment’s fastest growth.

The flow cytometry technique dominated the cell analysis industry

Based on technique, the global cell analysis market is segmented into flow cytometry, PCR, cell microarrays, microscopy, spectrophotometry, high-content screening, and other techniques. The flow cytometry segment accounted for the largest market share in 2022. Increase in demand for flow cytometry in single-cell analysis studies to analyze multiple characteristics of the sample at single-cell level is the key driving factor of this segment. Additionally, high-content screening segment has registerd highest growth ratefrom 2023-2028, with high demand for HCS products in cell behavior studies.

The single-cell analysis segment of the cell analysis industry is expected to register the highest CAGR during the forecast period

Based on process, the global cell analysis market is segmented into cell identification, cell viability, cell signaling pathway/signal transduction, cell proliferation, cell counting & quality control, cell interaction, cell structure study, target identification & validation, and single-cell analysis. Cell identification accounted for the largest market share of in 2022. High adoption of cell identification products across industrial applications, including food and healthcare is a key contributing factor to the segment growth. Cell identification is crucial to drug discovery and high adoption of these products have propelled companies to introduce innovative products. On the other hand, single-cell analysis segment is expected to grow at the fastest pace during the forecast period. Single-cell analysis has gained significant traction over the years for assessment of individual cells at multi-parametric level, contributing to the segment growth.

The pharmaceutical & biotechnology companies accounted for the largest share in the cell analysis industry

Based on end user, the cell analysis market is segmented into pharmaceutical & biotechnology companies, hospitals & clinical testing laboratories, academic & research institutes, and other end users. The other end users are inclusive of forensic laboratories, blood banks, CROs, food & beverage manufacturers, and environmental monitoring organizations. The pharmaceutical & biotechnology companies segment accounted for the largest market share in 2022. Frequent adoption of consumables and instruments across different steps in drug discovery & development has led to the dominance of pharmaceutical & biotechnology end users. Additionally, hospitals and clinical testing laboratories segment is anticipated to grow at the fastest pace throughout the forecast period. Adoption of highly complex and specialized assays across this end user segment is expected to support its rapid growth.

North America was the largest regional market for cell analysis industry in 2022.

Geographically, the cell analysis market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. North America region is expected to dominate the market through 2021-2028, followed by Europe. The US pharmaceutical industry has witnessed tremendous growth due to the increasing approval of first-in-class drugs by the Food and Drugs Administration (FDA), rising R&D expenditure by pharmaceutical companies, and the establishment of startups focusing on developing promising drugs for rare diseases and neurological conditions. This has propelled cell-based research activities, offering lucrative opportunities for the growth of the market in the US. Asia Pacific market is expected to grow at the fastest pace through 2023 to 2028.

To know about the assumptions considered for the study, download the pdf brochure

Key players in the global cell analysis market include Danaher (US), Thermo Fisher Scientific (US), Becton, Dickinson and Company (US), General Electric (US), Merck KGaA (US), Agilent Technologies (US), Olympus Corporation (Japan), Miltenyi Biotec (US), Bio-Rad Laboratories (US), BioStatus Limited (UK), Fluidigm Corporation (US), NanoCellect Biomedical (US), Cell Biolabs (US), Creative Bioarray (US), Meiji Techno (US), Promega Corporation (US), PerkinElmer (US), Tecan Trading AG (Switzerland), CELLINK (US), QIAGEN (Germany), Corning Incorporated (US), 10x Genomics (US), and Illumina (US).

Scope of the Cell Analysis Industry

This report categorizes the cell analysis market to forecast revenue and analyze trends in each of the following submarkets:

By Product & Service

• Reagents & Consumables
• Instruments
• Accessories
• Software
• Service

By Technique

• Flow Cytometry
• PCR
• Cell Microarrays
• Microscopy
• Spectrophotometry
• High Content Screening
• Other Techniques

By Process

• Cell Identification
• Cell Viability
• Cell Signaling Pathways/Signal Transduction
• Cell Proliferation
• Cell Counting and Quality Control
• Cell Interaction
• Cell Structure Study
• Target Identification and Validation
• Single-Cell Analysis

By End User

• Pharmaceutical & Biotechnology Companies
• Hospitals and Clinical Testing Laboratories
• Academic and Research Institutes
• Other End Users

By Region

• North America
  • US
  • Canada
• Europe
  • Germany
  • France
  • Italy
  • Spain
  • UK
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • Rest of Asia Pacific
• Latin America
• Middle East & Africa

Recent Developments of Cell Analysis Industry

• In 2023, Becton, Dickinson and Company (US) launched a Spectral Cell Sorter that is coupled with high-speed cell imaging. this product combines real-time imaging technology with spectral flow cytometry.
• In 2020, Miltenyi Biotec (Germany) launched MACS GMP Tyto Cartridge, a GMP-compliant cell sorter..
• In 2020, Bio-Rad Laboratories, Inc. (US) acquired Celsee, Inc., a provider of instruments and consumables for the isolation, detection, and analysis of single cells. This acquisition expanded the company’s product offerings in the flow cytometry market..

Frequently Asked Questions (FAQ):

To speak to our analyst for a discussion on the above findings, click Speak to Analyst